After a slow 2017, first-quarter biopharma acquisition activity could signal a turnaround.
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
Eagerly pursuing all the latest fads and trends.
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.
Fewer smaller transactions seems to be driving the dip in dealmaking, while options deals are proving more popular.